Skip to main content

What the FDA labels say about taking them together

Canagliflozin and ritonavir

Canagliflozin's FDA label of June 11, 2026 names ritonavir in its drug interactions section; the ritonavir label PlainMeds reads does not name canagliflozin. The canagliflozin label: “UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA.”

Check it at the source: the canagliflozin FDA label on DailyMed (effective June 11, 2026, Janssen Pharmaceuticals, Inc.); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).

What does the canagliflozin label say about ritonavir?

Canagliflozin label, drug interactions

UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. … patients who require additional glycemic control [see and ]. Examples: Rifampin, phenytoin, phenobarbital, ritonavir

Source: FDA drug label (INVOKANA), Janssen Pharmaceuticals, Inc., effective June 11, 2026 (SPL set b9057d3b-b104-4f09-8a61-c61ef9d4a3f3), via openFDA; the full label on DailyMed

What does the ritonavir label say about canagliflozin?

Ritonavir's label (effective July 23, 2026) does not name canagliflozin in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Canagliflozin generic labelers
7Ritonavir generic labelers
CanagliflozinRitonavir
Labeled forHeart attack and coronary artery disease, Type 2 diabetes, Chronic kidney diseaseHIV
Boxed warningNoYes
Pharmacy cost (NADAC)$19.13 per tablet 100 mg tablet$0.607 per tablet 100 mg tablet
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?